Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk A/S
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes
To demonstrate superiority of once-weekly dosing of two dose levels (0.5 mg and 1.0 mg) of semaglutide versus placebo on glycaemic control in subjects with type 2 diabetes mellitus on basal insulin.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Liraglutide Effect and Action in Diabetes (LEAD-5): Effects on glycaemic control after once daily administration of liraglutide in combination with glimepiride and metformin versus glimepiride and metformin combination therapy, and versus insulin glargine added to glimepiride and metformin combination therapy in subjects with type 2 diabetes. A six-month randomised, double-blind, parallel-group, multi-centre, multi-national trial with an open-label treat-to-target insulin glargine control arm
To assess and compare the effect on glycaemic control (as measured by HbA1c) of once daily administration of liraglutide in combination with glimepiride and metformin versus glimepiride and metformin ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing the efficacy and safety of insulin degludec/liraglutide and insulin degludec in subjects with type 2 diabetes
To confirm the superiority of insulin degludec/liraglutide vs. insulin degludec in controlling glycaemia in subjects with type 2 diabetes.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
BEGIN™: EASY PM A trial comparing the efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
To confirm the efficacy of SIBA 200 U/ml three times weekly + metformin ± DPP-4 inhibitor in controlling glycaemia with respect to change from baseline in HbA1c after 26 weeks of treatment. This is do...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Inhaled human insulin with the AERx® iDMS as prandial monotherapy compared to combination therapy with metformin and glimepiride in type 2 diabetes: an eighteen-week, open-label, multicentre, randomised, parallel group trial with an eight-week extension to investigate efficacy and safety
To compare the effect of periprandial inhaled insulin administered with AERx with the effect of glimepiride and metformin combination therapy, on glycaemic control after 18 weeks of treatment (as meas...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A multi-national, open labelled, randomised, stratified, parallel group 36 week comparison of twice daily Biphasic Insulin Aspart 30 versus thrice daily Biphasic Insulin Aspart 50 and 70 all in combination with metformin in subjects with type 2 diabetes. (INTENSIMIX-trial)
To investigate if BIAsp 50-50-50(30) and BIAsp 70-70-70(30) is non-inferior, and superior in the event of non-inferiority, compared with BIAsp 30-30 all in combination with metformin with respect to g...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A 26-week trial comparing efficacy and safety of insulin degludec/insulin aspart BID and insulin degludec OD plus insulin aspart in subjects with type 2 Diabetes Mellitus treated with basal insulin in need of treatment intensification with mealtime insulin
The objective of this trial is to confirm the efficacy of IDegAsp BID in controlling glycaemia after 26 weeks of treatment. This is done by comparing the difference in change in glycosylated haemoglob...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
An extension trial to NN1250-3579 comparing safety and efficacy of NN1250 plus OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes
The primary objective is to investigate the long-term safety and tolerability of NN1250. This is done by comparing NN1250 to insulin glargine after 104 weeks of treatment (52 weeks of treatment in NN1...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: a 52-week, open-label, multinational, randomised, parallel trial to investigate long-term safety
The primary objective of this trial is to evaluate long-term pulmonary safety profiles comparing preprandial inhaled human insulin with preprandial subcutaneous (sc) injections of insulin aspart, both...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A
- To evaluate the immunogenicity of NNC 0129-0000-1003 (hereafter referred to as N8-GP) in previously treated patients with Haemophilia A - To evaluate the clinical efficacy of N8-GP in bleeding prop...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant